Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander...
June 26, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Added to Russell 3000® Index

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
May 05, 2023 07:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseasesLong-term data supporting soticlestat safety, tolerability and seizure-reduction...
May 01, 2023 06:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2...
April 27, 2023 14:30 ET | Source: Ovid Therapeutics Inc.

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop seizures among Lennox-Gastaut patients and...
April 10, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
March 13, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

OV329 Phase 1 trial is progressing on trackAn IV formulation candidate suitable for future clinical trials has been achieved for OV350, one of several compounds from the Company’s KCC2 activator...
March 09, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
March 08, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal excitation, including epilepsiesTwo preclinical seizure models...
February 28, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...